upcoming Event
Winter 2024
Investor Summit Virtual
40 MicroCap Presenters – November 21, 2024
9:00am-4:00pm ET – Company Presentations 8:00am-4:00pm – 1×1 Meetings
Q4 Presenters
TNXP
- Tonix submitted a New Drug Application to the FDA in October 2024.
- An FDA decision on the NDA is expected in 2025, with potential product launch in 2025 if approved.
URG
- Largest U.S. uranium miner
- Nuclear energy sector is in rapid growth
TMGEF
- Proprietary energy efficiency solutions provide high ROI
- Track record of profitable growth with significant repeat business from F500
TGCB
- Product, people, plan, opportunity = success
- Commercial success is in process
MFIN
- MFIN has a proven track record of growing loan portfolio.
- Above average NIM gives flexibility and options.
MAIA
- Unprecedented efficacy clinical data in current clinical trial with a supply agreement with Regeneron. Ongoing discussions with potential major pharma partners for next trials
- One of the most undervalued biotech stocks in Oncology: analysts project $10-14/share in 2025; analogs suggest $50-
AZ
- Timing of self-checkout, specifically Smart cart adoption, is starting to broadly happen among more and more grocery chains. Strong momentum with notable international and domestic grocery store and wholesale chains. Rollout and implementation of our smart carts to commence in earnest in Q1.
- Publicly announced two IT partnerships that represent two
NMTC
- Thin-film electrode platform technology with multiple market opportunities treating and diagnosing neurological disorders and pain.
- Improving financial profile. Now have 3 product families commercialized in the United States.
NRBO
- Targeting Obesity and MASH with a Pipeline of Next Generation Therapeutics
- Aiming to increase Shareholder Value through Multiple, Near-Term, Value Creating Milestones DA-1726
IMUX
- Immunic is developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases
- Top-line data from the phase 2 CALLIPER trial of vidofludimus calcium in PMS is expected in April 2025
BLGO
- Has a proven business model of inventing, proving, and partnering out its innovative environmental technologies, highlighted by the blockbuster success of its pet odor control product Pooph.
- Has innovations in high-yield, rapidly growing markets like battery energy storage and PFAS treatment that are superior to existing solutions in the market.
SOTK
- Consistently profitable with strong growth trajectory in disruptive high tech markets.
- Record revenue in Fiscal year 2024, 30% YOY growth.
ACFN
- Liquidity of the shares will improve with performance and as the price increases towards intrinsic value.
- Acorn's results are just starting to reflect a large contract with a leading Telecom provider.
OESX
- FY’25 revenue expected to increase 10% weighted toward the 2H.
- EV charging grew 40% in Q2; $7.5B of Federal funding appropriated for EV infrastructure.
FET
- Increasing global energy demand will propel long-term investment
- Global footprint and strategy execution will drive strong free cash flow
BENF
- Innovative access to private equity investments via public equity stock
- Transitioned to GAAP net income profitable operations in F1Q 2025 (June 30 Quarter End)
IMRN
- September 2024 Quarter AUD$1.5 million up 13% on prior quarter
- Sales of Travelan® increased 3% to AUD $1.007 million during September 2024 Quarter
LMFA
- Held 142.3 Bitcoin on September 30, 2024, Valued at Approximately $12.4 Million Based on Recent Bitcoin Price of $87,000
- Digital mining cost of revenues (exclusive of depreciation and amortization) as a percentage of digital mining revenues showed substantial improvement versus the prior year quarter.
ACON
- Industry 1st noninvasive diagnostic with strong clinical evidence of value
- Nearly 60% of all patients with private health insurance in the greater London market now have Access to Aclarion’s Nociscan
AUUD
- Leading the audio superapp space with differentiation & margin
- Accretive M&A strategy to accelerate revenue & user acquisitions
SNGX
- Robust pipeline with multiple fast track and/or orphan designated products, potential for significant commercial returns
- Late clinical-stage assets, one with successful Phase 3 data readout
CPSH
- Unique applications in rapidly-expanding markets
- Strong balance sheet
- New contract wins
- At inflection point for growth
ASNS
PERF
- Industry growth potential in beauty/fashion tech
- PERF's strength and innovations for growth in B2B (SAAS) and B2C (suite of apps under YouCam brand).
ULY
- Leading proprietary digitally native mobility services platform
- Uniquely positioned to further penetrate $25B B2B incident business opportunity
PLUR
- $10m raise in EverAfter Foods from Global Food Giants as Strategic Partners
- Innovative collaborations with multi-national agriculture corporations - €1 million POC project
